Greenwich LifeSciences (NASDAQ: GLSI) is recognized as an exceptionally volatile clinical-stage biopharmaceutical equity. Because it operates as a micro-cap company with low daily trading volumes and a singular primary drug candidate in late-stage clinical trials, the stock is prone to sharp, double-digit percentage swings within single trading sessions. Movements frequently occur independently of broad market trends and can be triggered by minor shifts in trading liquidity, speculative retail interest, or broad clinical sentiment.